Reader-submitted picks ranked by how often they were chosen, each marked to 2025 performance. Stance reflects whether Slegers argues a view in this post: Positive where he endorses or defends the name, Neutral where he only describes it. Research legend: QT Qualtrim · SA Seeking Alpha · STK Stock Analysis. Foreign primary listings keep this source's suffixed row ids. Written post with no timestamps — the At link opens the article.
| Ticker | Name | Research | View | What he said | At |
|---|---|---|---|---|---|
| KNSL | Kinsale Capital | QT · SA · STK · FA | Positive | #3 most-picked; −13.9% in 2025 — and the issue's strongest endorsement. "Kinsale Capital had a tough year. Currently, the company is facing increased competition. The market punished this compounder too hard if you ask me. It could be a great buying opportunity." Three independent confirmations are stacked: director Gregory M. Share bought $1.05 million of stock; the board authorised a $250 million buyback (2.7% of market cap); and "François Rochon, one of the best quality investors in the world, recently increased his stake." Closing line: "How many buy signals do you want?" — with the stock "near its cheapest valuation level ever." | read ↗ |
| EVO.ST | Evolution AB | QT · SA · STK | Positive | #1 most-picked and the year's worst answer: −28.5%. "It got nearly three times as many votes as the second pick, MercadoLibre. However, it was a terrible year for Evolution." Causes named: growth slowed, and "Asia remains a weak spot: revenue from that region declined due to ongoing issues with cyber-attacks." The defence is a re-classification rather than a rebuttal — "The company went from a high-growth stock to a value play. At this price, the company looks really cheap. I think a lot of bad news is already priced in" — with the stock "trading at its lowest valuation level ever." | read ↗ |
| KPG.AX | Kelly Partners Group Holdings | STK | Positive | #8 most-picked; −22.9% — and the issue's cleanest value-vs-price divergence: "Kelly Partners Group grew its intrinsic value (Owner's Earnings) by 22.6% last year. Yet the stock moved in the opposite direction… The result? The company became 45% cheaper!" Brett Kelly is quoted explaining the absent buyback as a capital constraint rather than a valuation judgment: "We are currently limited by the capital available… We're overwhelmed with opportunities, so we haven't done any buybacks… If we had extra capital, we would be buying back shares enthusiastically and on a large scale." Slegers' read: "Brett Kelly clearly thinks the stock is undervalued at today's price." | read ↗ |
| DNP.WA | Dino Polska | SA · STK | Positive | #9 most-picked; +3.1%. The market's complaint is named and answered: "The market was not happy about the slowing like-for-like growth… Am I worried about this? Not really." Two reasons. (1) The country: Poland's GDP per capita has gone from $13,600 in 1995 (36% of the UK's) to $44,500 (81%), growing "ten times faster" than the UK in real terms since 2019 — sourced to Michael Gielkens of Tresor Capital. (2) The arithmetic: "In the first nine months of 2025, total revenue grew by 14.9%… The limited sales growth of existing stores is more than offset by the sales growth from new stores." Biedronka is named as the comparison on the like-for-like chart. | read ↗ |
| TOI.V | Topicus.com | QT · SA · STK | Positive | #5 most-picked; +1.2% — the operating-vs-share-price split stated in one line: "Topicus had an amazing 2025. The company spent more capital on acquisitions in 2025 than the last three years combined. However, the stock didn't do well… Investors worry that VMS businesses are an easy target for AI disruption." The concern is taken seriously enough that "Constellation Software, Topicus' parent company, held a conference call specifically to discuss the (potential) impact of AI." Verdict: "I personally don't believe AI will disrupt VMS companies like Constellation Software and Topicus." | read ↗ |
| MELI | MercadoLibre | QT · SA · STK · FA | Neutral | #2 most-picked; +14.1% — and the one name in the top three that is not endorsed. The growth record is extraordinary: "the only public company to grow its revenue for more than 22 consecutive quarters at +30%." The price is the objection: "Yet the stock was 'only' up about 13% last year. In other words, MercadoLibre became cheaper last year. Today, MercadoLibre trades at about 40.2x forward earnings. This is obviously not cheap but it could be justified if MercadoLibre keeps growing at attractive rates." A conditional, not a recommendation. | read ↗ |
| ASML | ASML Holding | QT · SA · STK · FA | Neutral | #4 most-picked; +33.5%. Descriptive: "ASML dominates the market for EUV lithography machines. In fact, it's a monopoly. As a monopoly, you can regularly raise your prices because no one makes the same products as you," plus the AI tailwind — "The market clearly noticed this in 2025." No valuation and no stance; the same monopoly framing recurs in Arka Bhattacharjee's 20-year list. | read ↗ |
| GOOGL | Alphabet | QT · SA · STK · FA | Neutral | #6 most-picked; +65.2% — the year's clearest sentiment reversal, reported without a house view. "Google's search faces its biggest threat: people are turning to AI chatbots like ChatGPT… fewer searches mean less ad money. But today, many believe Google is leading the AI race. OpenAI CEO Sam Altman has declared a 'code red' as the company scrambles to catch up with Google's Gemini 3 models." | read ↗ |
| TMDX | TransMedics Group | QT · SA · STK · FA | Neutral | #7 most-picked and the best performer on the list at +82.9%. Organ-transplant technology: "Instead of storing organs on ice, TransMedics devices keep them warm and working outside the body. This helps doctors better evaluate organs before surgery." The house label is applied without a valuation attached: "Revenue increased sharply. The company remained profitable despite higher costs from expansion. That's exactly what a high-quality compounder does." | read ↗ |
| MELE.BR | Melexis NV | STK | Neutral | #10 most-picked; +3.8% — the only automotive-cycle name on the list. "Melexis makes small chips used in machines, especially cars… Electric cars need far more chips than traditional cars." Two problems named: "The car industry is having a tough time" and "Melexis faces more competition." The mitigation is diversification — "they are launching more and more products outside the automotive sector." Reported, not rated. | read ↗ |
Note the shape of the list against its 4 January sibling. Ranked by popularity, the crowd picks quality compounders — seven of these ten pass the house screen and four are portfolio holdings — and the results are mediocre (three of the ten fell). Ranked by return, the same readership's winners are cyclical and speculative. The two lists are drawn from the same survey and point in opposite directions, which is the most useful thing about publishing both. Also worth flagging: the two issues quote the same year's index return differently (+17.1% here, +16% on 4 January) and the same readership's average differently (+19.0% here, +17.3% there) — different cuts of the sample, so neither figure travels.
A jargon-free summary of the thesis behind each argued name. (Renders on each name's consolidated page.)
Kinsale insures the awkward risks ordinary insurers turn away — the unusual property, the hard-to-price liability. Because those policies are not standardised, a disciplined underwriter can charge properly for what it is taking on.
The shares fell 13.9% in 2025 because more competitors moved into that market, which pushes prices down for everyone. Slegers thinks the reaction is out of proportion, and rather than argue from his own model he points at three people acting with their own money: a director of the company bought about a million dollars of stock, the board authorised buying back 2.7% of the company, and François Rochon — an investor with a long record in exactly this style — added to his position. His line is "how many buy signals do you want?"
The thing to hold on to is the logic, not the enthusiasm: insurance pricing runs in cycles, and a firm with a genuine cost advantage survives the soft part of the cycle that removes weaker competitors. If that is true of Kinsale, the competition that caused the fall is temporary and the fall is the opportunity.
Evolution films real croupiers running blackjack, roulette and baccarat tables in studios and streams those games into online casinos, which pay to license them. It was the most popular pick among readers for 2025 by a wide margin — three times as many votes as second place — and it fell 28.5%.
Slegers does not defend the year. He reclassifies the investment: "the company went from a high-growth stock to a value play." Growth slowed, and Asia — where cyber-attacks on the studios have been a recurring problem — went backwards. What he argues is that the price now assumes those problems continue forever, which is what "trading at its lowest valuation level ever" means in practice.
That is a legitimate argument and also a convenient one, because it lets a disappointing growth holding stay in the portfolio under a new label. The honest way to track it is to watch whether the cash actually comes back to shareholders: by mid-2026 the case rests almost entirely on the buyback retiring a large share of the company each year rather than on the business growing.
Kelly Partners buys small Australian accounting firms — tax, bookkeeping, business advice — taking a controlling stake while leaving the local partners with a share, so they keep caring about the result.
The number that matters in this write-up is the gap between two things that usually move together. The underlying value of the business, measured as owner's earnings, rose 22.6% in 2025. The share price fell 22.9%. Put those together and you are paying about 45% less for each pound of profit than a year earlier, with nothing having gone wrong operationally.
The founder agrees, and the way he says so is the useful detail. Asked why the company is not buying back its own cheap shares, Brett Kelly answers that every available pound is already committed to buying more accounting firms — "we're overwhelmed with opportunities" — and that with spare capital he would be repurchasing "enthusiastically and on a large scale." A company with more good uses for money than money is a specific and checkable kind of good problem.
Dino Polska runs mid-sized grocery supermarkets in Polish small towns and villages, close to where people live, and has been opening them at an extraordinary rate.
The worry in 2025 was that sales at existing stores had almost stopped growing — the measure retailers call like-for-like — which is usually the first sign a chain has saturated its market or is losing to a competitor. Slegers concedes the number and answers it twice. First, the rest of the business swamps it: total revenue still grew 14.9% over nine months because the new stores more than make up for the flat old ones. Second, the country itself is the tailwind — Poland's income per head has gone from roughly a third of Britain's in 1995 to four-fifths today, and has grown about ten times faster than the UK's in real terms since 2019.
Worth noting what that second argument commits him to. The case now depends on Poland continuing to converge on Western Europe, which is a macro bet rather than a company one — and it is exactly the exposure his own September 2026 rule change (developed markets only) later rules out.
Topicus buys small software companies across Europe whose products run one specific industry — a hospital's records system, a municipality's tax software — and reinvests the cash they produce into buying more of them.
2025 was the paradox this archive keeps returning to: the business had its best year of capital deployment ever, spending more on acquisitions than in the previous three years combined, while the share price went nowhere. The reason is a fear rather than a fact — that artificial intelligence will make it cheap to rebuild this kind of niche software, destroying the pricing power that makes the model work.
Slegers rejects it, and the interesting evidence is that the fear was serious enough for the parent company, Constellation Software, to hold a call devoted to answering it. His own answer arrives two weeks later in the portfolio update: writing the code was never the hard part — knowing the industry, and being the supplier a hospital or a council will actually let near its operations, is.
MercadoLibre is Latin America's Amazon and PayPal in one company: an online marketplace plus a payments arm, Mercado Pago, that takes another fee on the same transaction.
The growth record is genuinely without peer — more than 22 straight quarters of revenue growing over 30% a year — and the shares rose only about 14% in 2025, which mechanically makes them cheaper than they were.
And Slegers still does not buy them. At about 40 times next year's earnings his verdict is a conditional: "obviously not cheap, but it could be justified if MercadoLibre keeps growing at attractive rates." That is worth reading carefully, because it is the whole discipline in one sentence — the business passes and the price does not, and no amount of quality is allowed to substitute for the second test.
Summary derived from the archived Compounding Quality post (text in transcript.txt) for personal study. Not investment advice. © Compounding Quality / Pieter Slegers for source material.